Tobias Kiesslich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/193054/publications.pdf

Version: 2024-02-01

69 papers	1,497 citations	304368 22 h-index	360668 35 g-index
69 all docs	69 docs citations	69 times ranked	2742 citing authors

#	Article	IF	Citations
1	Epigenetic control of epithelial-mesenchymal-transition in human cancer. Molecular and Clinical Oncology, 2013, 1, 3-11.	0.4	100
2	MiRâ€96â€5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Molecular Carcinogenesis, 2015, 54, 1442-1450.	1.3	81
3	Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2016, 17, 573.	1.8	66
4	Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. Anticancer Research, 2015, 35, 5737-44.	0.5	61
5	The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complementary and Alternative Medicine, 2015, 15, 194.	3.7	57
6	Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. Hepatology, 2015, 62, 1456-1465.	3.6	56
7	SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS ONE, 2017, 12, e0187814.	1.1	56
8	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology, 2019, 25, 3136-3150.	1.4	51
9	Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Human Pathology, 2017, 65, 41-52.	1.1	49
10	A Comprehensive Tutorial onIn VitroCharacterization of New Photosensitizers for Photodynamic Antitumor Therapy and Photodynamic Inactivation of Microorganisms. BioMed Research International, 2013, 2013, 1-17.	0.9	47
11	The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget, 2016, 7, 745-758.	0.8	38
12	Reasons for Journal Impact Factor Changes: Influence of Changing Source Items. PLoS ONE, 2016, 11, e0154199.	1.1	35
13	Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 2011.	1.8	32
14	Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochemical and Photobiological Sciences, 2010, 9, 734-743.	1.6	31
15	IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget, 2017, 8, 89736-89745.	0.8	30
16	Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochemical and Photobiological Sciences, 2009, 8, 23-30.	1.6	29
17	Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology. Current Pharmaceutical Biotechnology, 2012, 13, 2184-2220.	0.9	29
18	Methylsulfonyl Zn phthalocyanine: A polyvalent and powerful hydrophobic photosensitizer with a wide spectrum of photodynamic applications. Photodiagnosis and Photodynamic Therapy, 2016, 13, 40-47.	1.3	27

#	Article	IF	Citations
19	Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model. Oncology Letters, 2017, 15, 2913-2920.	0.8	27
20	Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells. International Journal of Biological Sciences, 2012, 8, 15-29.	2.6	25
21	Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncology Letters, 2014, 7, 745-749.	0.8	25
22	Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World Journal of Gastrointestinal Oncology, 2015, 7, 473.	0.8	25
23	Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers, 2022, 14, 1826.	1.7	23
24	The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International Journal of Oncology, 2015, 47, 963-970.	1.4	22
25	The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics. Cancers, 2019, 11, 276.	1.7	22
26	New Applications of Photodynamic Therapy in Biomedicine and Biotechnology. BioMed Research International, 2013, 2013, 1-3.	0.9	20
27	HDAC-Linked â€œProliferativeâ€•miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors. International Journal of Molecular Sciences, 2018, 19, 2781.	1.8	20
28	Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. BioMed Research International, 2016, 2016, 1-15.	0.9	19
29	Singleâ€•center implementation of endoscopic submucosal dissection (<scp>ESD</scp>) in the colorectum: Low recurrence rate after intentionâ€•toâ€•treat <scp>ESD</scp>. Digestive Endoscopy, 2018, 30, 354-363.	1.3	19
30	The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. Human Pathology, 2018, 72, 117-126.	1.1	19
31	3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. Anticancer Research, 2015, 35, 4697-705.	0.5	19
32	MicroRNAs Associated with the Efficacy of Photodynamic Therapy in Biliary Tract Cancer Cell Lines. International Journal of Molecular Sciences, 2014, 15, 20134-20157.	1.8	18
33	The role of polycomb repressive complexes in biliary tract cancer. Expert Opinion on Therapeutic Targets, 2015, 19, 363-375.	1.5	18
34	Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 199.	0.5	18
35	HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers, 2021, 13, 3862.	1.7	17
36	Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. International Journal of Oncology, 2010, 36, 49-58.	3.9	16

#	Article	IF	Citations
37	Citation inequality and the Journal Impact Factor: median, mean, (does it) matter?. Scientometrics, 2021, 126, 1249-1269.	1.6	15
38	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. International Journal of Molecular Sciences, 2016, 17, 2053.	1.8	14
39	Long Non-Coding RNAs in Biliary Tract Cancerâ€"An Up-to-Date Review. Journal of Clinical Medicine, 2020, 9, 1200.	1.0	14
40	Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations. Anticancer Research, 2015, 35, 6127-36.	0.5	14
41	Biliary tract cancer stem cells - translational options and challenges. World Journal of Gastroenterology, 2017, 23, 2470.	1.4	13
42	Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncology, 2010, 6, 1925-1936.	1.1	12
43	Association of stem cell marker expression pattern and survival in human biliary tract cancer. International Journal of Oncology, 2012, 41, 511-522.	1.4	12
44	Glycine Induces Migration of Microglial BV-2 Cells via SNAT-Mediated Cell Swelling. Cellular Physiology and Biochemistry, 2018, 50, 1460-1473.	1.1	12
45	Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group. European Journal of Surgical Oncology, 2019, 45, 198-206.	0.5	12
46	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. Cancers, 2020, 12, 1235.	1.7	12
47	GERDâ€"Barrettâ€"Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?. Gastroenterology Research and Practice, 2013, 2013, 1-14.	0.7	11
48	Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2017, 26, 133-136.	1.9	11
49	Real-time analysis of endogenous protoporphyrin IX fluorescence from Î´-aminolevulinic acid and its derivatives reveals distinct time- and dose-dependent characteristicsin vitro. Journal of Biomedical Optics, 2014, 19, 085007.	1.4	10
50	Systematic Review on Optical Diagnosis of Early Gastrointestinal Neoplasia. Journal of Clinical Medicine, 2021, 10, 2794.	1.0	9
51	Miniaturization of the Clonogenic Assay Using Confluence Measurement. International Journal of Molecular Sciences, 2018, 19, 724.	1.8	8
52	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
53	Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2016, 4, 763-773.	0.4	7
54	MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers, 2021, 13, 3996.	1.7	7

#	Article	IF	Citations
55	Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma. Cells, 2019, 8, 539.	1.8	6
56	Photosensitizer Adhered to Cell Culture Microplates Induces Phototoxicity in Carcinoma Cells. BioMed Research International, 2013, 2013, 1-11.	0.9	5
57	Endoscopic submucosal dissection (ESD) for anal high-grade intraepithelial neoplasia: a case report. Zeitschrift Fur Gastroenterologie, 2018, 56, 495-498.	0.2	5
58	HDAC inhibitors in liver cancer: which route to take?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 515-517.	1.4	5
59	Size matters! Association between journal size and longitudinal variability of the Journal Impact Factor. PLoS ONE, 2019, 14, e0225360.	1.1	5
60	Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?. Expert Opinion on Investigational Drugs, 2022, 31, 221-233.	1.9	5
61	The H+/K+ ATPase Inhibitor SCH-28080 Inhibits Insulin Secretion and Induces Cell Death in INS-1E Rat Insulinoma Cells. Cellular Physiology and Biochemistry, 2017, 43, 1037-1051.	1.1	4
62	Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 1-3.	1.5	4
63	NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?. EBioMedicine, 2019, 49, 9-10.	2.7	4
64	Generation of An Endogenous FGFR2â€“BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. International Journal of Molecular Sciences, 2020, 21, 2460.	1.8	3
65	Evidence-based Surgery of Aortic Regurgitation: Results of a Questionnaire in German-speaking Countries. Thoracic and Cardiovascular Surgeon, 2018, 66, 287-293.	0.4	1
66	Continuous, label-free, 96-well-based determination of cell migration using confluence measurement. Cell Adhesion and Migration, 2019, 13, 76-82.	1.1	1
67	The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 591-594.	1.9	1
68	Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancersâ€”reply. Human Pathology, 2018, 71, 167-168.	1.1	0
69	How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?. Expert Opinion on Pharmacotherapy, 2020, 21, 243-245.	0.9	0